Head-To-Head Contrast: Insulet (PODD) vs. T2 Biosystems (TTOO)

Insulet (NASDAQ:PODD) and T2 Biosystems (NASDAQ:TTOO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

Insulet has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.



Profitability

This table compares Insulet and T2 Biosystems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Insulet -3.47% -11.91% -2.32%
T2 Biosystems -637.62% -556.22% -91.71%

Earnings & Valuation

This table compares Insulet and T2 Biosystems’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insulet $463.77 million 10.69 -$26.83 million ($0.46) -182.67
T2 Biosystems $4.66 million 46.59 -$62.42 million N/A N/A

Insulet has higher revenue and earnings than T2 Biosystems.

Insider & Institutional Ownership

59.1% of T2 Biosystems shares are owned by institutional investors. 3.6% of Insulet shares are owned by company insiders. Comparatively, 31.5% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Insulet and T2 Biosystems, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet 0 3 12 1 2.88
T2 Biosystems 0 1 5 0 2.83

Insulet presently has a consensus price target of $97.80, suggesting a potential upside of 16.39%. T2 Biosystems has a consensus price target of $9.05, suggesting a potential upside of 82.46%. Given T2 Biosystems’ higher probable upside, analysts clearly believe T2 Biosystems is more favorable than Insulet.

Summary

Insulet beats T2 Biosystems on 9 of the 13 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply